Metastatic hormone receptor-positive breast cancer in CDK 4/6 era | Zendy

Rajeev Krishnappa Lakkavalli | Zendy; Jitendra Kumar Pehalajani | Zendy; Tirumala Venkatesh | Zendy; G.K. Babu | Zendy; Dassappa Loknatha | Zendy; LinuAbraham Jacob | Zendy; Suresh M. C. Babu | Zendy; A.H. Rudresha | Zendy; Lokesh Nagendrappa Kadabur | Zendy; Smitha C. Saldanha | Zendy; G. V. Giri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metastatic hormone receptor-positive breast cancer in CDK 4/6 era

Author(s) -

Rajeev Krishnappa Lakkavalli,

Jitendra Kumar Pehalajani,

Tirumala Venkatesh,

G.K. Babu,

Dassappa Loknatha,

LinuAbraham Jacob,

Suresh M. C. Babu,

A.H. Rudresha,

Lokesh Nagendrappa Kadabur,

Smitha C. Saldanha,

G. V. Giri

Publication year - 2020

Publication title -

journal of cancer research and therapeutics

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/jcrt.jcrt_853_18

Subject(s) - metastatic breast cancer , medicine , breast cancer , hormone receptor , oncology , hormone , cancer , toxicity , metastasis , retrospective cohort study , cyclin dependent kinase , gastroenterology , cell cycle

The treatment landscape of metastatic hormone receptor (HR) positive breast cancer has been changed in recent years. Availability of CDK 4/6 inhibitor and other hormone therapy has changed the treatment algorithm for these patient, we retrospectively analyzed our metastatic HR positive breast cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research